Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia

Drug Name

Doptelet/avatrombopag

Developer

Dova Pharmaceuticals

Therapy Class

Thrombopoietin (TPO) receptor agonist

Current Indication

Thrombocytopenia in chronic liver disease (CLD)

Market Sector

Haematology

Development Status

Approved in the US
Expand

Go Top